THMO - ThermoGenesis Holdings, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
+0.41 (+8.89%)
At close: 3:55PM EST
Stock chart is not supported by your current browser
Previous Close4.61
Bid4.50 x 900
Ask5.01 x 4000
Day's Range4.51 - 5.05
52 Week Range2.40 - 7.00
Avg. Volume57,851
Market Cap14.275M
Beta (5Y Monthly)1.04
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • PR Newswire

    ThermoGenesis Holdings Closes Joint Venture Agreement With HealthBanks Biotech (USA) To Form ImmuneCyte Life Sciences

    ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that the company has closed on its joint venture agreement with HealthBanks Biotech (USA) Inc., a leading stem cell bank network. The joint venture, called ImmuneCyte Life Sciences, Inc. ("ImmuneCyte"), has been formed in order to commercialize ThermoGenesis' proprietary cell processing platform, CAR-TXpress™, for use in immune cell banking as well as for cell-based contract development and manufacturing services (CMO/CDMO).